LexBlog IP

DECEMBER 13, 2023

The post Janssen and Samsung Bioepis Settle STELARA (Ustekinumab) Litigation appeared first on Big Molecule Watch.

Litigation 52

Litigation Settlement Licensing Marketing 52

LexBlog IP

MARCH 6, 2024

announced it has signed a settlement agreement with Bayer Inc. The settlement resolves multiple patent infringement proceedings in the Federal Court of Canada. Under the agreement, Biocon can launch YESAFILI in Canada no later than July 1, 2025. On March 4, Biocon Biologics Ltd. and Regeneron Pharmaceuticals, Inc.

Marketing 52

Marketing Marketing Settlement Litigation 52

Biswajit Sarkar Copyright Blog

DECEMBER 19, 2023

As India aims for a $5 trillion economy, the MSME ministry sets ambitious goals, aiming to elevate their GDP contribution by up to 50% by 2025. Subsidies offered for Patent and Trademark (in selected categories) registration, encouraging innovation and protecting intellectual property.

Settlement 52

Settlement Intellectual Property Registration Designs 52

LexBlog IP

NOVEMBER 5, 2023

As we covered previously , Janssen and Amgen settled their BPCIA litigation regarding Amgen’s ustekinumab biosimilar product in May 2023. ” (CMS’s position on this has been challenged in pending litigation.) WEZLANA is the first product to be approved as a biosimilar to STELARA.

Marketing 40

Marketing Marketing Government Litigation 40

LexBlog IP

JANUARY 25, 2024

Janssen and Amgen settled their BPCIA litigation regarding Amgen’s ustekinumab biosimilar product in May 2023. ” (CMS’s position on this has been challenged in pending litigation.) WEZLANA is the first product to be approved as a biosimilar to STELARA.

Marketing 52

Marketing Marketing Licensing Litigation 52

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 4, 2021

Yet 2020 saw a slowdown in biosimilar activity with the lowest number of annual biosimilar approvals since 2016 and fewer product launches than 2019—as well as a decrease in district court litigation and post-grant proceedings. BPCIA Litigation. Antitrust Litigation. No earlier than July 31, 2023 per settlement.

Litigation 52

Litigation Settlement Marketing Marketing 52

Patently-O

MAY 15, 2024

This wave of RFCs includes significant proposals aimed at adjusting patent fees for fiscal year 2025, refining terminal disclaimer practices, and addressing the impact of artificial intelligence on prior art and patentability. 325(d) considerations, parallel and serial petitions, and settlement-related terminations.

Art 44

Art Intellectual Property Designs Design 44